A detailed history of Ubs Asset Management Americas Inc transactions in Legend Biotech Corp stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 106,533 shares of LEGN stock, worth $4.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
106,533
Previous 330,323 67.75%
Holding current value
$4.28 Million
Previous $18.5 Million 74.53%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$39.5 - $57.22 $8.84 Million - $12.8 Million
-223,790 Reduced 67.75%
106,533 $4.72 Million
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $1.65 Million - $2.09 Million
29,917 Added 9.96%
330,323 $18.5 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $2.18 Million - $2.65 Million
38,001 Added 14.48%
300,406 $18.1 Million
Q3 2023

Nov 13, 2023

BUY
$63.16 - $76.5 $3.03 Million - $3.67 Million
47,947 Added 22.36%
262,405 $17.6 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $1.39 Million - $1.83 Million
31,961 Added 17.51%
214,458 $10.3 Million
Q4 2022

Feb 14, 2023

SELL
$38.8 - $55.46 $12.1 Million - $17.3 Million
-312,379 Reduced 63.12%
182,497 $9.11 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $371,466 - $555,982
9,737 Added 2.01%
494,876 $20.2 Million
Q2 2022

Aug 12, 2022

BUY
$33.54 - $55.0 $10.7 Million - $17.6 Million
320,007 Added 193.79%
485,139 $26.7 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $1.39 Million - $2.16 Million
44,798 Added 37.23%
165,132 $6 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $4.95 Million - $6.86 Million
120,334 New
120,334 $5.61 Million
Q3 2020

Nov 13, 2020

SELL
$27.5 - $39.61 $687,500 - $990,250
-25,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$36.1 - $42.56 $902,500 - $1.06 Million
25,000 New
25,000 $1.06 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.